Sfoglia per AUTORE
GALLI M
Collezione AO Cuneo

  

Items : 5

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Tacchetti P; Zucchetta P; Pascarella A; Villanova T; De Cicco G; Patriarca F; Fioritoni F; Priola C; Sgherza N; Grasso M; Versari A; Bertamini L; Gamberi B; Albano D; Zambello R; Racca M; Galli M; Belotti A; D'Agostino M; Rota-Scalabrini D; Capra A; Gay F; Oliva S; Zamagni E; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Boccadoro M; Cavo M; Corradini P; Petrucci MT; Zambello R; Gamberi B; Aquino S; Palmas A; de Fabritiis P; Giuliani N; D'Agostino M; Capra A; Patriarca F; Cea M; Spadano A; Grasso M; Ballanti S; Zamagni E; Ledda A; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino
AO Cuneo

Sonneveld P; Boccadoro M; Carvalho S; Spencer A; Palmas A; Cafro AM; Minnema M; Mandigers C; van Marwijk Kooy M; Gimsing P; Mellqvist UH; Waage A; Driessen C; Specchia G; Zander T; Caravita di Toritto T; Durian M; von dem Borne PA; Hajek R; Wu KL; Boersma R; Morelli AM; Aquino S; Ludwig H; Levin MD; Bos G; Pascarella A; Benevolo G; Troia R; et alii...

Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients. in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis / Transfus Apher Sci. 2018 Oct;57(5):639-645. doi: 10.1016/j.transci.2018.06.005. Epub 2018 Jun 26.

2018
AO Cuneo

Galli M; Accorsi P; De Silvestro G; Oreni L; Quartuccio L; Fraticelli P; Ferri C; Zani R; Marenchino D; D'Alessandri G; Moretto M; Capuzzo E; Filippini D; Mascia MT; Castelnovo L; Riva A; Marson P; Monti G; Montani F;

Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. in Haematologica / Haematologica. 2018 Oct;103(10):e469-e472. doi: 10.3324/haematol.2017.182865. Epub 2018 Apr 26.

2018
AO Cuneo

Nagler A; Sanderson RD; Rambaldi A; Pace S; Paoletti D; Barbieri P; Celeghini I; Einsele H; Magen H; Specchia G; Grasso M; Galli M; Chatterjee M;